What question did this study set out to answer?

To determine whether polymorphisms in the renin-angiotensin system can predict blood pressure-lowering response to treatment with irbesartan or atenolol in patients with hypertension.

October 1, 2001Journal of Hypertension

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

View Full Paper

Ask AI

Bookmark

Why the study?

Does ACE gene polymorphism predict blood pressure response to irbesartan compared to atenolol in hypertensive patients?

Population

86 patients with hypertension

Comparison

Irbesartan vs Atenolol

Design

RCT, randomized, double-blind

Follow-up

3 months

Authors

LKLisa KurlandUppsala University HMHåkan MelhusUppsala University JKJulia KarlssonLinköping University

Discussion

Member takes

Implication

May inform ACE genotype-guided irbesartan selection in hypertension; extends pharmacogenomic interaction data from RCTs.

Key Points

To determine whether polymorphisms in the renin-angiotensin system can predict blood pressure-lowering response to treatment with irbesartan or atenolol in patients with hypertension.
Randomized, double-blind trial in 86 patients with hypertension assigned to either irbesartan or atenolol and followed for 3 months.
Genotyped angiotensinogen (T174M, M235T), angiotensin converting enzyme (ACE I/D), and angiotensin II type 1 receptor (A1166C) polymorphisms to evaluate associations with blood pressure changes.
Irbesartan-treated patients homozygous for the ACE I allele showed significantly greater diastolic blood pressure reduction compared to D allele carriers (-18 ± 11 mmHg vs. -7 ± 10 mmHg, P = 0.0096).
The interaction between treatment type and ACE II genotype was statistically significant (P = 0.0176), with no genotype-dependent response observed in the atenolol group.
Angiotensinogen and angiotensin II type 1 receptor polymorphisms showed no significant relationship with blood pressure reduction in either treatment group.

Structured PICO

Does ACE gene polymorphism predict blood pressure response to irbesartan compared to atenolol in hypertensive patients?

Population

86 patients with hypertension

Intervention

Irbesartan

Comparator

Atenolol

Outcome

Blood pressure reduction related to renin-angiotensin system polymorphisms (angiotensinogen T174M and M235T, ACE I/D, and angiotensin II type 1 receptor A1166C)surrogate

ACE genotyping (specifically the I allele) predicts a greater diastolic blood pressure-lowering response to irbesartan, but not atenolol, suggesting a potential role for pharmacogenomics in targeted hypertension management.

Cite This Study

Kurland et al. (2001) studied this question.

synapsesocial.com/papers/6a70d62935aa2c282ce228d7 https://doi.org/10.1097/00004872-200110000-00012

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider